Modifying ART in the Presence of Hyperlipidemia: Using HIV-ASSIST

In this episode, Maunank Shah, MD, PhD, discusses using HIV-ASSIST to optimize treatment for both HIV and hyperlipidemia. Listen as he covers:Hyperlipidemia and cardiovascular disease risk among people living with HIVRecommendations for lipid screening for people living with HIVUsing HIV-ASSIST to support ART treatment decisions for people living with HIV with comorbiditiesHow HIV-ASSIST prioritizes certain ART agents in the setting of hyperlipidemia, including:Deciding between bictegravir, doravirine, dolutegravir, raltegravir, and rilpivirine vs boosted protease inhibitors, including darunavirDeciding between tenofovir disoproxil fumarate and tenofovir alafenamide or abacavirHow HIV-ASSIST incorporates drug‒drug interaction data from the University of Liverpool HIV Drug Interactions Checker and the DHHS guidelines when considering the use of statin therapy with ARTHow HIV-ASSIST further incorporates drug resistance data from the Stanford HIV Drug Resistance DatabaseMaunank Shah, MD, PhD Associate Professor Infectious Diseases Johns Hopkins University Baltimore, Maryland Link to full program: bit.ly/3pwaH2Y